FY2024 EPS Estimate for Alto Neuroscience Boosted by Analyst

Alto Neuroscience, Inc. (NYSE:ANRO) – Stock analysts at William Blair increased their FY2024 EPS estimates for Alto Neuroscience in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($2.65) for the year, up from their previous estimate of ($2.73). William Blair has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.60) per share. William Blair also issued estimates for Alto Neuroscience’s Q4 2024 earnings at ($0.70) EPS, Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.47) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($2.21) EPS and FY2028 earnings at ($3.06) EPS.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05.

Several other equities research analysts have also commented on ANRO. RODMAN&RENSHAW lowered Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Rodman & Renshaw cut shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus reduced their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Wedbush cut shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Finally, Robert W. Baird cut their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Alto Neuroscience Stock Down 1.7 %

ANRO opened at $4.52 on Monday. The firm’s fifty day simple moving average is $9.69 and its two-hundred day simple moving average is $11.30. The company has a quick ratio of 19.85, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 52-week low of $3.61 and a 52-week high of $24.00.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently made changes to their positions in ANRO. BNP Paribas Financial Markets increased its holdings in Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after purchasing an additional 3,715 shares during the period. Rhumbline Advisers purchased a new position in Alto Neuroscience in the second quarter worth approximately $113,000. Jane Street Group LLC acquired a new position in Alto Neuroscience during the 3rd quarter worth approximately $124,000. Federated Hermes Inc. raised its holdings in shares of Alto Neuroscience by 33.3% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after purchasing an additional 3,000 shares in the last quarter. Finally, MetLife Investment Management LLC purchased a new stake in shares of Alto Neuroscience during the 3rd quarter worth $146,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.